Table 3 IVF exposure and breast cancer risk in BRCA1 mutation carriers

From: Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers

 

BC+a

BC−a

HR (95% CI)b

n = 1550

630 (40.7)

920 (59.4)

 

IVF treatment

  No

616 (97.8)

889 (96.6)

1.00

  Yes

12 (1.9)

29 (3.2)

1.12 (0.60–2.09)

  Missing

2 (0.3)

2 (0.2)

 

Age at first IVF (%)c

  Median (min–max, years)

31.1 (23–36)

32.3 (24–42)

 

  No IVF

616 (97.8)

889 (96.6)

1.00

  ≤32 years

7 (1.1)

14 (1.5)

1.91 (0.88–4.16)

  >32 years

5 (0.8)

15 (1.6)

0.70 (0.28–1.76)

  Missing

2 (0.3)

2 (0.2)

 

Time since first IVF treatment (%)c

  No IVF

616 (97.8)

889 (96.6)

1.00

  <5 years ago started

6 (1.0)

13 (1.4)

1.15 (0.49–2.66)

  ≥5 years ago started

6 (1.0)

16 (1.7)

1.10 (0.47–2.56)

  Missing

2 (0.3)

2 (0.2)

 

Time since last IVF treatment (%)c

  No IVF

616 (97.8)

889 (96.6)

1.00

  <2 years ago stopped

5 (0.8)

7 (0.8)

1.49 (0.60–3.73)

  ≥2 years ago stopped

5 (0.8)

21 (2.3)

0.84 (0.33–2.10)

  Age of last treatment before censoring unknown

2 (0.3)

1 (0.1)

 

  Missing

2 (0.3)

2 (0.2)

 
  1. BC breast cancer, HR hazard ratio, CI confidence interval, IVF in vitro fertilisation.
  2. aDistribution of variable at time of censoring.
  3. bInstrinsically stratiefied on birth year (1940–1957, 1958–1968, 1969–1993); adjusted for subfertility (no, yes, missing).
  4. cCutoffs of categories in variables related to IVF characteristics are based on number of cases available in the exposed group